CHICAGO--(BUSINESS WIRE)--GE Healthcare today announced results of a unique partnership with Fred Hutchinson Cancer Research Center and the Center for Sustainable Health at Arizona State University. This partnership is directed at identifying areas in oncology where diagnostics could provide high value through reducing costs, while at the same time maintaining or improving patient outcomes. Focusing on colorectal cancer, researchers brought leading US experts in colorectal cancer care, health policy, and insurance to discuss opportunities for diagnostics to improve clinical care. Following the recommendations of this expert panel, the team created a decision-based model to estimate the potential cost-effectiveness of biomarker-directed use of bevacizumab versus current practice in the first-line treatment of metastatic colorectal cancer.1
